title: [Effects of ursodeoxycholic acid on mRNA expression of MDR3 and FXR in infants with cholestatic hepatitis].
abstract: OBJECTIVE
  To analyze the effects of ursodeoxycholic acid (UDCA) on the mRNA expression of multidrug resistance protein 3 (MDR3) and farnesoid X receptor (FXR) in infants with cholestatic hepatitis.
  
  
  METHODS
  Twenty-eight infants who were diagnosed with cholestatic hepatitis between July 2008 and July 2010 were included in the study. These patients received treatment with UDCA. The mRNA expression levels of MDR3 and FXR were measured by real-time quantitative RT-PCR with SYBR Green I, before and after treatment with UDCA.
  
  
  RESULTS
  After treatment with UDCA, the infants with cholestatic hepatitis had significantly decreased serum levels of total bilirubin, direct bilirubin, alanine aminotransferase, and gamma-glutamyltransferase (P<0.05) and significantly increased mRNA expression of MDR3 (P<0.05). No significant change in mRNA expression of FXR was observed, however (P>0.05).
  
  
  CONCLUSIONS
  UDCA improves liver function indices in infants with cholestatic hepatitis, which may be related to up-regulated mRNA expression of MDR3.
authors.affiliation: Second Department of Pediatrics, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China. peiqing55@foxmail.com.
authors.forename: Qing
authors.initials: Q
authors.lastname: Tang
authors.forename: Lin-Lin
authors.initials: LL
authors.lastname: Wang
authors.forename: Qing-Wen
authors.initials: QW
authors.lastname: Shan
authors.forename: Xiang
authors.initials: X
authors.lastname: Yun
authors.forename: Xiu-Qi
authors.initials: XQ
authors.lastname: Chen
authors.forename: Ya-Nan
authors.initials: YN
authors.lastname: Deng
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000235:genetics*; D002779:Cholestasis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation; D006505:Hepatitis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006801:Humans; D007223:Infant; D008297:Male; D012333:RNA, Messenger / Q000032:analysis*; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics*; D014580:Ursodeoxycholic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D012333:RNA, Messenger; D018160:Receptors, Cytoplasmic and Nuclear; D014580:Ursodeoxycholic Acid; D000099150:Receptor, Farnesoid X-Activated; C095122:multidrug resistance protein 3